Swedish stent maker Jomed plans market listing:
This article was originally published in Clinica
Jomed, a Swedish manufacturer of cardiac minimally-invasive devices, plans a stock market listing by 2000 that could value the company at up to Euro800 million ($862 million). It is believed the Helsingborg-based group will list in Frankfurt rather than Stockholm. In 1998, the company's sales grew by 68% to Euro25.5 million, while profits almost tripled to Euro6.1 million. Jomed has expanded rapidly since its launch in the early 1990s, reflecting the corresponding growth in minimally-invasive surgery in the hospital sector.
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.